Segment Information (Tables)

12 Months Ended

Dec. 31, 2024

Segment Reporting [Abstract]

Summary of Segment Performance and Make Decisions About Resource Allocation

The following table contains information on segment profit or loss, including significant segment expenses (in thousands):

	YEAR ENDED DECEMBER 31,
	2024			2023
Revenue	$	251		$	33,492
Less:
AB-101		19,978			14,090
Other programs(a)		330			3,797
Personnel-related		30,465			28,610
Other(b)		16,760			17,666
Other income, net		1,909			2,023
Provision for income taxes		—			(72	)
Net loss	$	(65,373	)	$	(28,720	)

(a)Other programs primarily includes costs associated with AB-201, Merck, and Affimed.

(b)Other primarily includes consultant, depreciation, rent, common area maintenance, lab supplies, legal, and insurance expenses.